Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Health

Report Published: "Humira (Crohn's Disease) - Forecast and Market Analysis to 2022"


Print article Print article
2014-03-22 11:16:40 - Fast Market Research recommends "Humira (Crohn's Disease) - Forecast and Market Analysis to 2022" from GlobalData, now available

The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge the current biologics in an attempt to dislodge the stronghold of the TNF inhibitors, as they aim to tap into the lucrative portion of the CD therapeutics market. If their promising safety and efficacy profiles translate to clinical practice once they enter the market, their launch will be to the detriment of the existing market leaders, Remicade (infliximab) and Humira (adalimumab).The loss of patent protection of the anti-TNF marketed brands will allow for the emergence of biosimilars, such as Hospira's Inflectra (infliximab) a Remicade biosimilar. Focusing on country dynamics, Canada and the emerging markets of China and India will also

play a key role in driving growth in the long term, with each market forecast to post positive Compound Annual Growth Rates (CAGRs) from 2012 to 2022, primarily due to the anticipated strong uptake of Remicade over the forecast period.

Full Report Details at
- www.fastmr.com/prod/782735_humira_crohns_disease_forecast_and_ma ..

Humira is a recombinant human IgG1 mAb that binds to TNF-a and blocks its interaction with p55 and p75 cell-surface receptors, which reduces inflammation and stops tissue destruction. It was the first fully-humanized mAb TNF inhibitor to enter the market for the treatment of CD in the US in 2007. It is considered a first-line biologic therapy option and is indicated for the treatment of adults with moderately to severely active disease who have had an inadequate response to conventional therapy, as well as for patients with a loss of response or intolerance to Remicade.

Report Scope

* Overview of Crohn's disease (CD), including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
* Detailed information on Humira including product description, safety and efficacy profiles as well as a SWOT analysis.
* Sales forecast for Humira for the top nine countries from 2012 to 2022.
* Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, China and Canada

Reasons to Get this Report

* Understand and capitalize by identifying products that are most likely to ensure a robust return
* Stay ahead of the competition by understanding the changing competitive landscape for Crohn's disease
* Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
* Make more informed business decisions from insightful and in-depth analysis of Humira performance
* Obtain sales forecast for Humira from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, China and Canada)

Report Table of Contents:

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
2.3 Upcoming Related Reports 10
3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 11
3.2 Symptoms 15
3.3 Prognosis 16
3.4 Quality of Life 16
4 Disease Management 17
4.1 Treatment Overview 18
5 Competitive Assessment 23
5.1 Overview 23
5.2 Strategic Competitor Assessment 24
6 Humira (adalimumab) 26
6.1 Overview 26
6.2 Efficacy 27
6.3 Safety 28
6.4 SWOT Analysis 28
6.5 Forecast 30
7 Appendix 33
7.1 Bibliography 33
7.2 Abbreviations 36
7.3 Methodology 38
7.4 Forecasting Methodology 38
7.4.1 Diagnosed CD Patients 38
7.4.2 Percent Drug-Treated Patients 39
7.4.3 General Pricing Assumptions 39
7.4.4 Individual Drug Assumptions 40
7.4.5 Generic Erosion 41
7.5 Physicians and Specialists Included in This Study 42
7.6 Primary Research - Prescriber Survey 44
7.7 About the Authors 45
7.7.1 Author/Reviewer 45
7.7.2 Global Head of Healthcare 45
7.8 About GlobalData 46
7.9 Disclaimer 46


List of Tables

1.1 List of Tables
Table 1: Symptoms of CD 15
Table 2: Treatment Guidelines for CD 19
Table 3: Most Commonly Prescribed Drugs for CD in the Global Markets by Disease Severity, 2013 21
Table 4: Leading Branded Drugs Used to Treat CD 25
Table 5: Product Profile - Humira 27
Table 6: Humira SWOT Analysis, 2013 30
Table 7: Global Sales Forecasts ($) for Humira, 2012-2022 32
Table 8: Physicians Surveyed, By Country 44

List of Figures

1.2 List of Figures
Figure 1: Mucosa of the Bowel in a Healthy Individual (Left) and a Patient With CD (Right) 12
Figure 2: Potential Biologic Drug Targets for CD 14
Figure 3: Patient Care Path for CD 20

About GlobalData

GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team. View more research from GlobalData at www.fastmr.com/catalog/publishers.aspx?pubid=1015

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.


Author:
Bill Thompson
e-mail
Web: www.fastmr.com
Phone: 18008448156

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com